Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Laura Guarga
Observed names:
Guarga, Laura,
L Guarga,
L. Guarga,
L. Guarga Sole,
Laura Guarga-Solé
Institutions:
Institut d'Investigació Biomédica de Bellvitge,
Departament de Salut,
Institut Català d'Oncologia
Observed institutions:
Universitat Autònoma de Barcelona,
Universitat Pompeu Fabra,
Institut d'Investigació Biomédica de Bellvitge,
Departament de Salut,
Institut Català d'Oncologia,
UPF Barcelona School of Management
show all 6
ORCID:
0000-0001-5960-2442
Observed ORCID:
0000-0001-5960-2442
OpenAlex ID:
A5085113818
Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut)
2019
·
Laura Guarga
, Xavier Badia
, et al.
·
Orphanet Journal of Rare Diseases
·
75
PDF
Trends in lung cancer incidence by age, sex and histology from 2012 to 2025 in Catalonia (Spain)
2021
·
Laura Guarga
, Alberto Ameijide
, et al.
·
Scientific Reports
·
38
PDF
Patient involvement in reflective multicriteria decision analysis to assist decision making in oncology
2019
·
Xavier Badia
, Alfonso Aguarón
, et al.
·
International Journal of Technology Assessment in Health Care
·
25
Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain)
2022
·
Montse Gasol
, Noelia Paco
, et al.
·
Journal of Clinical Medicine
·
18
PDF
Implementing Risk-Sharing Arrangements for Innovative Medicines: The Experience in Catalonia (Spain)
2021
·
Laura Guarga
, Montse Gasol
, et al.
·
Value in Health
·
16
PDF
Application Of Multi-Criteria Decision Analysis (MCDA) To Determine The Value Of Treatments For The Moderate To Severe Plaque Psoriasis In Spain
2017
·
X Badia
, P de la Cueva
, et al.
·
Value in Health
·
12
PDF
Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia
2021
·
Anna Reyes-Travé
, Laura Guarga-Solé
, et al.
·
PharmacoEconomics
·
10
PDF
149TiP DEFINITIVE TRIAL: Diagnostic HER2DX-guided treatment for patIents wIth early-stage HER2-positive breast cancer
2025
·
T. Pascual
, M. González Rodríguez
, et al.
·
ESMO Open
·
6
PDF
Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study
2023
·
Gemma Garrido-Alejos
, Guillem Saborit-Canals
, et al.
·
Cancers
·
3
PDF
Management, Survival, and Costs of Pancreatic Cancer: Population-Based Observational Study in Catalonia
2023
·
Laura Guarga
, Noelia Paco
, et al.
·
International Journal of Environmental Research and Public Health
·
3
PDF
Changes in Treatment Patterns and Costs for Lung Cancer Have Not Resulted in Relevant Improvements in Survival: A Population-Based Observational Study in Catalonia
2022
·
Laura Guarga
, Noelia Paco
, et al.
·
Cancers
·
2
PDF
Php23 - Comparing Risk Sharing Agreements in Catalonia With Others Eu Countries
2018
·
L. Guarga
, E. Fondevilla
, et al.
·
Value in Health
·
2
Patient Empowerment for Healthcare Decision-Making Assessing Oncology Innovation Through Multicriteria Decision Analysis
2017
·
A Aguarón
, A Fernández
, et al.
·
Value in Health
·
2
Consensus-based validation of key quality indicators in pancreatic cancer surgery in Catalonia: a modified Delphi study
2026
·
Laura Guarga
, Patricia Sánchez-Velázquez
, et al.
·
Cirugía Española
·
1
HTA8 The Catalan Health Service, An Example Where Patients Have Full Medicine Appraisal and Decision-Making Representation
2022
·
M Gasol
, M Fontanet
, et al.
·
Value in Health
·
1
PDF
Psy49 - Budgetary Impact of Orphan Drugs in the Catalan Healthcare Service
2018
·
M. Fontanet
, M. Obach
, et al.
·
Value in Health
·
1
PDF
Development Of An Specific Evaluation Framework For Orphan Drugs Based On Multi-Criteria Decision Analysis (MCDA) For Health Care Decision Making In Catalonia
2017
·
X Badia
, C Pontes
, et al.
·
Value in Health
·
1
Access to Orphan Drugs (ODS) in Spain Compared with EU4 Countries: Inequity and Lack of Price Transparency Across Europe
2017
·
X Badia
, A Gil
, et al.
·
Value in Health
·
1
PDF
Response to: “Re: ‘Consensus-based validation of key quality indicators in pancreatic cancer surgery in Catalonia: a modified Delphi study’”
2026
·
Paula Manchon-Walsh
, Patricia Sánchez-Velázquez
, et al.
·
Cirugía Española (English Edition)
223P Health policy and real-world strategies in early-stage HER2-positive breast cancer: results from an international survey within the DEFINITIVE project
2026
·
G. Rapesta
, V. Retel
, et al.
·
ESMO Open
Consensus-based validation of key quality indicators in pancreatic cancer surgery in Catalonia: a modified Delphi study
2026
·
Laura Guarga
, Patricia Sánchez-Velázquez
, et al.
·
Cirugía Española (English Edition)
Care pathways for integrating regional cancer services: multiple-case study in five European settings
2026
·
Andreu Albiach
, Joan Prades
, et al.
·
SSRN Electronic Journal
Management, survival, and costs of pancreatic cancer: Popupation-Based observational study in Catalonia
2023
·
Guarga, Laura
, Paco, Noelia
, et al.
·
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
RWD85 Trends in Medicine Utilization and Its Expenditure for Treating Lung Cancer in Catalonia
2022
·
L Guarga
, D Gay
, et al.
·
Value in Health
PDF
Managing shortage of intensive care drugs during the COVID-19 pandemic in Catalonia
2021
·
Marc López‐Roig
, Laura Guarga
, et al.
·
European Journal of Clinical Pharmacology
Show more works
View as search
Works count:
31
Citation count:
217
H-index:
7
I10-index:
7
Year
Topic
Type